Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Q2 2022 Earnings Conference Call August 8, 2022 4:30 PM ET

Company Participants

Meredith Kaya - SVP, IR & Strategic Finance

Adam Townsend - Chief Commercial Officer

Cedric Francois - Co-Founder, President, CEO & Director

Timothy Sullivan - CFO & Treasurer

Federico Grossi - Chief Medical Officer

Conference Call Participants

Madhu Kumar - Goldman Sachs Group

Umer Raffat - Evercore

Anupam Rama - JPMorgan

Tazeen Ahmad - Bank of America

Lyla Youssef - Cowen

Steven Seedhouse - Raymond James

Colleen Kusy - RW Baird

Derek Archila - Wells Fargo

Justin Kim - Oppenheimer

Yigal Nochomovitz - Citi

Ellie Merle - UBS

Annabel Samimy - Stifel

Douglas Tsao - H.C. Wainwright

Operator

Ladies and gentlemen, thank you for standing by and welcome to the Apellis Pharmaceuticals Second Quarter 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. [Operator Instructions].

I'd now like to turn the call over to your host Meredith Kaya. You may begin.

Meredith Kaya

Good afternoon, and thank you for joining us to discuss Apellis's second quarter 2022 financial results. With me on the call are Co-Founder and Chief Executive Officer, Dr. Cedric Francois; Chief Commercial Officer, Adam Townsend; Chief Medical Officer, Dr. Federico Grossi; and Chief Financial Officer, Tim Sullivan.

Before we begin, I would like to point out on Slide 3, that we will be making forward-looking statements that are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. I encourage you to consult the risk factors discussed in our SEC filings for additional detail.

Now, I'll turn the call over to Cedric.

Cedric Francois

Thank you all for joining us today. 2022 is a transformational year at Apellis and we are making great progress across each of our key priorities. I'll start with geographic atrophy, or GA. A few weeks ago, we were thrilled to announce that our NDA for intravitreal pegcetacoplan was accepted by the FDA with a priority reviews designation and the PDUFA date of November 26, 2022. The FDA also stated that it is not planning to hold an advisory committee meeting to discuss the application. This is the best outcome we could have hoped for and I am so proud of the Apellis team for their efforts in getting us to this pivotal point.